HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age.

AbstractOBJECTIVE:
To evaluate the clinical efficacy and patient satisfaction of danazol delivered vaginally as treatment for young women with menorrhagia.
DESIGN:
Prospective study.
SETTING:
University of Siena, Siena, Italy.
PATIENT(S):
Women with menorrhagia (n = 55; age range 25-35 years) after ultrasound and hysteroscopy.
INTERVENTION(S):
Low-dose danazol (200 mg/day) was daily administered by vaginal route for 6 months.
MAIN OUTCOME MEASURE(S):
Before and every month during the treatment women were requested: 1) to keep a diary of menstrual bleeding and to rate blood loss on a visual analog scale from 0 (no blood loss) to 10 (gushing-type bleeding); 2) to record side effects and their satisfaction with the therapy. Transvaginal ultrasound, blood count, serum chemistries, and serum concentration of LH, FSH, E(2), TSH, FT(3), FT(4), and PRL were evaluated before and after 6 months.
RESULT(S):
The severity of blood loss was significantly reduced in all of the women after 2 months of treatment. Uterine volume was significantly reduced, and hematocrit, hemoglobin, and red blood cell count increased in all of the women after 6 months. The medical treatment did not affect hormonal parameters, and menstrual cycle remained unaffected; few local vaginal adverse effects were recorded.
CONCLUSION(S):
Vaginal danazol resulted in effective medical treatment in young women with menorrhagia, and, because of a lack of significant adverse effects, it may be proposed as an alternative treatment.
AuthorsStefano Luisi, Sandro Razzi, Lucia Lazzeri, Caterina Bocchi, Filiberto M Severi, Felice Petraglia
JournalFertility and sterility (Fertil Steril) Vol. 92 Issue 4 Pg. 1351-1354 (Oct 2009) ISSN: 1556-5653 [Electronic] United States
PMID18930222 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Estrogen Antagonists
  • Hemoglobins
  • Danazol
Topics
  • Administration, Intravaginal
  • Adult
  • Age Factors
  • Danazol (administration & dosage)
  • Erythrocyte Count
  • Estrogen Antagonists (administration & dosage)
  • Female
  • Fertility (drug effects, physiology)
  • Hematocrit
  • Hemoglobins (analysis)
  • Humans
  • Menorrhagia (blood, drug therapy, physiopathology)
  • Patient Satisfaction
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: